We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 02 JANUARY 2014
Federal Circuit Invalidates Galderma Differin Patents
Foley & Lardner LLP
In Galderma Laboratories v. Tolmar, Inc., the Federal Circuit reversed the district court’s findings that the Orange Book-listed patents for Galderma’s Differin® 0.3% gel product were not invalid as obvious.
United StatesIntellectual Property









